Erratum: Dual E1A oncolytic adenovirus: Targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT (Cancer Gene Therapy (2011) 18 (153-166) DOI: 10.1038/cgt.2010.52);Dual E1A oncolytic adenovirus: Targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT

Cancer Gene Therapy

Volumn 18, Issue 3, 2011, Pages 153-166

  Doloff, J C ^a   Waxman, D J ^a  

^a Boston University   (United States)

Author keywords

cytochrome P450 prodrug activation; holoclone; oncolytic adenovirus; replication conditional; tumor heterogeneity

Indexed keywords

DF3 PROTEIN; E1A PROTEIN; E1B PROTEIN; MUCIN 1; ONCOLYTIC ADENOVIRUS; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR PROMOTER; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CELL DEATH; CELL ISOLATION; CELL POPULATION; CONTROLLED STUDY; GENE CASSETTE; GENE DELETION; GENE EXPRESSION; GENETIC HETEROGENEITY; GLIOSARCOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROMOTER REGION; PROTEIN EXPRESSION; SARCOMA CELL; TUMOR CELL; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION;

ADENOVIRIDAE;

EID: 79951725000     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.1     Document Type: Erratum

References (50)

1. Bauerschmitz GJ, Barker SD, Hemminki A. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review). Int J Oncol 2002; 21: 1161-1174.
2. Jounaidi Y, Doloff JC, Waxman DJ. Conditionally Replicating Adenoviruses for Cancer Treat (Pubitemid 46699079)
3. Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer gene ther 2005; 12: 141-161. (Pubitemid 40205096)
4. Nevins JR. Mechanism of activation of early viral transcription by the adenovirus E1A gene product. Cell 1981; 26 (2 Pt 2): 213-220. (Pubitemid 12244499)
5. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
6. Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG et al. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 2003; 63: 579-585. (Pubitemid 36158134)
7. Doloff JC, Waxman DJ, Jounaidi Y. hTERT-promoter driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions. Hum Gene Ther 2008; 19: 1383-1400.
8. Wirth T, Kuhnel F, Kubicka S. Telomerase-dependent gene therapy. Curr Mol Med 2005; 5: 243-251. (Pubitemid 40601653)
9. Cozzi PJ, Wang J, Delprado W, Perkins AC, Allen BJ, Russell PJ et al. MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis 2005; 22: 565-573. (Pubitemid 43234641)
10. Hinoda Y, Ikematsu Y, Horinochi M, Sato S, Yamamoto K, Nakano T et al. Increased expression of MUC1 in advanced pancreatic cancer. J Gastroenterol 2003; 38: 1162-1166. (Pubitemid 38128828)
11. Ho SB, Niehans GA, Lyftogt C, Yan PS, Cherwitz DL, Gum ET et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993; 53: 641-651. (Pubitemid 23059449)
12. Nagai S, Takenaka K, Sonobe M, Ogawa E, Wada H, Tanaka F. A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer. J Thorac Oncol 2006; 1: 46-51. (Pubitemid 47164020)
13. Khodarev NN, Pitroda SP, Beckett MA, MacDermed DM, Huang L, Kufe DW et al. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res 2009; 69: 2833-2837.
14. Li Y, Liu D, Chen D, Kharbanda S, Kufe D. Human DF3/ MUC1 carcinoma-associated protein functions as an onco-gene. Oncogene 2003; 22: 6107-6110. (Pubitemid 37175889)
15. Fessler SP, Wotkowicz MT, Mahanta SK, Bamdad C. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Res Treat 2009; 118: 113-124.
16. Yin L, Li Y, Ren J, Kuwahara H, Kufe D. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem 2003; 278: 35458-35464. (Pubitemid 37102316)
17. Engelmann K, Shen H, Finn OJ. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res 2008; 68: 2419-2426. (Pubitemid 351521817)
18. Hikita ST, Kosik KS, Clegg DO, Bamdad C. MUC1* mediates the growth of human pluripotent stem cells. PLoS One 2008; 3: e3312.
19. Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG. PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res 2008; 68: 1820-1825. (Pubitemid 351416567)
20. Jounaidi Y, Chen CS, Veal GJ, Waxman DJ. Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. Mol Cancer Ther 2006; 5: 541-555.
21. Jounaidi Y, Waxman DJ. Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. Cancer Res 2004; 64: 292-303. (Pubitemid 38114110)
22. Jounaidi Y, Hecht JE, Waxman DJ. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res 1998; 58: 4391-4401. (Pubitemid 28450042)
23. Abe M, Kufe D. Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene. Proc Natl Acad Sci USA 1993; 90: 282-286. (Pubitemid 23010294)
24. Kovarik A, Lu PJ, Peat N, Morris J, Taylor-Papadimitriou J. Two GC boxes (Sp1 sites) are involved in regulation of the activity of the epithelium-specific MUC1 promoter. J Biol Chem 1996; 271: 18140-18147. (Pubitemid 26250804)
25. Kovarik A, Peat N, Wilson D, Gendler SJ, Taylor-Papadimitriou J. Analysis of the tissue-specific promoter of the MUC1 gene. J Biol Chem 1993; 268: 9917-9926. (Pubitemid 23146057)
26. Abou El Hassan MA, van der Meulen-Muileman I, Abbas S, Kruyt FA. Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. J Virol 2004; 78: 12243-12251. (Pubitemid 39458744)
27. Moreb JS. Aldehyde dehydrogenase as a marker for stem cells. Curr Stem Cell Res Ther 2008; 3: 237-246.
28. Yuan A, Chen JJ, Yao PL, Yang PC. The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci 2005; 10: 853-865.
29. Chen CS, Lin JT, Goss KA, He YA, Halpert JR, Waxman DJ. Activation of the anticancer prodrugs cyclo-phosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol 2004; 65: 1278-1285. (Pubitemid 38543498)
30. Crompton AM, Kirn DH. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets 2007; 7: 133-139. (Pubitemid 46348627)
31. Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther 2002; 13: 1737-1750. (Pubitemid 35191748)
32. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000; 106: 763-771.
33. Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther 2010; 18: 429-434.
34. Francis P, Fernebro J, Eden P, Laurell A, Rydholm A, Domanski HA et al. Intratumor versus intertumor heterogeneity in gene expression profiles of soft-tissue sarcomas. Genes Chromosomes Cancer 2005; 43: 302-308. (Pubitemid 40726875)
35. Nagasaki K, Miki Y. Gene expression profiling of breast cancer. Breast Cancer 2006; 13: 2-7.
36. Leedham SJ, Wright NA. Expansion of a mutated clone: from stem cell to tumour. J Clin Pathol 2008; 61: 164-171. (Pubitemid 351218875)
37. Mimeault M, Hauke R, Mehta PP, Batra SK. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 2007; 11: 981-1011. (Pubitemid 350037046)
38. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99: 1441-1454.
39. Walsh MD, Luckie SM, Cummings MC, Antalis TM, McGuckin MA. Heterogeneity of MUC1 expression by human breast carcinoma cell lines in vivo and in vitro. Breast Cancer Res Treat 1999; 58: 255-266. (Pubitemid 30113877)
40. Yan P, Benhattar J, Seelentag W, Stehle JC, Bosman FT. Immunohistochemical localization of hTERT protein in human tissues. Histochem Cell Biol 2004; 121: 391-397. (Pubitemid 38756936)
41. Hao X, Sun B, Hu L, Lahdesmaki H, Dunmire V, Feng Y et al. Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 2004; 100: 1110-1122. (Pubitemid 38325937)
42. Bauerschmitz GJ, Ranki T, Kangasniemi L, Ribacka C, Eriksson M, Porten M et al. Tissue-specific promoters active in CD44+CD24-/low breast cancer cells. Cancer Res 2008; 68: 5533-5539.
43. Ribacka C, Pesonen S, Hemminki A. Cancer, stem cells, and oncolytic viruses. Ann Med 2008; 40: 496-505.
44. Hale TK, Braithwaite AW. The adenovirus oncoprotein E1a stimulates binding of transcription factor ETF to transcriptionally activate the p53 gene. J Biol Chem 1999; 274: 23777-23786.
45. Rao XM, Tseng MT, Zheng X, Dong Y, Jamshidi-Parsian A, Thompson TC et al. E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells. Cancer gene ther 2004; 11: 585-593. (Pubitemid 39195408)
46. 0s sarcoma animal model. Mol Cancer Ther 2003; 2: 1313-1319.
47. Deissler H, Opalka B. Therapeutic transfer of DNA encoding adenoviral E1A. Recent Pat Anticancer Drug Discov 2007; 2: 1-10. (Pubitemid 46723150)
48. Liao Y, Yu D, Hung MC. Novel approaches for chemo-sensitization of breast cancer cells: the E1A story. Adv Exp Med Biol 2007; 608: 144-169.
49. Martin-Duque P, Sanchez-Prieto R, Romero J, Martinez-Lamparero A, Cebrian-Sagarriga S, Guinea-Viniegra J et al. In vivo radiosensitizing effect of the adenovirus E1A gene in murine and human malignant tumors. Int J Oncol 1999; 15: 1163-1168.
50. Waxman DJ, Schwartz PS. Harnessing apoptosis for improved anticancer gene therapy. Cancer Res 2003; 63: 8563-8572. (Pubitemid 38064026)